Goosebumps, Here are Dr Campbell’s observatio

Goosebumps,

Here are Dr Campbell’s observations from August 6.

“ I’ve been in medicine over 40 years and if you had told me the scenario setting up Pro-140 before this past year, I wouldn’t have believed you. I watched a presentation last night on how Leronlimab inhibits inflammation and augments the immune system. This mechanisms of action makes unbelievably good preliminary results in triple negative breast cancer survival possible with none of the side effects of chemotherapy. Most other Inflammation and autoimmune diseases are now known to include an overexpression of the ccr5 receptor, which can be modulated by Leronlimab. Of course this includes the Cytokine storm phase of severe Covid. The number of diseases and cancers that might be treatable with Leronlimab are so numerous I cannot list them here. That said though, do not underestimate the threat this molecule poses to the big Pharma companies. I’ve had big Pharma veterans tell me it absolutely is in the big companies’ interest to squash CYDY in any way possible, which includes market manipulation of share price on a grand scale. Also you also must remember that even though the FDA is funded largely by fees from Big Pharma, astounding results from Brazil will be widely publicized and hard to ignore if this second wave persists into winter. In the last CC Scott Kelly kept talking about the value of a BTD designation and that historically all small pharmaceutical companies were acquired by big Pharma after two. I think he’s inferring that positive Brazil trials and/or one or two BTD will push us to either partnership or buyout at a good price snd get quicker FDA approvals than what would be possible for a tiny company. There are so many possibilities for this drug that it will take a large company with hundreds of guys like Recknor to explore all the possibilities. However, whichever company partners with CYDY will I think become the dominant pharmaceutical company for the foreseeable future. If we do get bought out, I’d suggest holding the stock of whoever buys us.”